Data from Pharmawand - Curated by EPG Health - Date added 14 November 2017
Theravance Biopharma, Inc. and Mylan N.V. announced the submission of a New Drug Application (NDA) to the FDA for revefenacin (TD 4208), an investigational long-acting muscarinic antagonist (LAMA) as a once-daily, nebulized bronchodilator in development for the treatment of chronic obstructive pulmonary disease (COPD).
The NDA is supported by the companies' Phase III program for revefenacin, which consisted of two replicate pivotal Phase III efficacy studies and a 12-month, open-label, active comparator safety study.
Comment:This submission represents a key step in efforts to bring the first once-daily nebulized LAMA to the COPD patient community. While a significant number of COPD patients require or prefer nebulized therapy, these same patients currently have no access to a nebulized LAMA, broadly considered the cornerstone of COPD maintenance therapy.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Allergic Rhinitis
Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.
+ 4 more
Cystic Fibrosis
View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.
+ 1 more
ALP Lab Assessment
Discover and overview of hypophosphatasia and details required to facilitate the timely and accurate detection of low alkaline phosphatase.
Acute and Advanced Heart Failure
What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...
+ 3 more
Migraine Knowledge Centre
The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.
Communicating Metastatic Breast Cancer Learning Zone
This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.
Related Content
IMPACT study of Trelegy Ellipta in COPD published in NEJM.- GlaxoSmithKline + Innoviva.
GlaxoSmithKline and Innoviva announced the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study, one...
Added 6 days ago
DYNAGITO trial results of Stiolto Respimat in chronic obstructive pulmonary disease published in The Lancet Respiratory Medicine.- Boehringer.
Boehringer announced that data from the DYNAGITO trial, a 52-week study involving more than 7,800 people across a broad range...
Added 27 days ago
CHMP recommends CHF 5993 for maintenance treatment of COPD.- Chiesi Farmaceutici.
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing...
Added 1 month ago
CLAIM study of Ultibro Breezhaler shows reduction of lung hyperinflation in COPD patients.-Novartis.
Novartis announced the publication of the CLAIM study in the Lancet Respiratory Medicine, which demonstrated that treatment once-daily Ultibro Breezhaler...
Added 2 months ago
Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease.
We hypothesized that long-term use of tiotropium would improve lung function and ameliorate the decline in lung function in patients with mild or moderate COPD.
Added 2 months ago
The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
The objective of the FAVOR study was to evaluate the effect of indacaterol/glycopyrronium (IND/GLY) versus tiotropium on peak forced expiratory volume in 1 s (FEV1) and also to investigate patient satisfaction and treatment preference.
Added 2 months ago
Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Indacaterol/glycopyrronium (IND/GLY) 110/50mcg was the first once-daily, long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) approved in Europe for the treatment of...
Added 2 months ago
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
Purpose: To compare the efficacy and safety of two long-acting dual bronchodilator combinations: indacaterol/glycopyrrolate (IND/GLY) versus umeclidinium/vilanterol (UMEC/VI).
Added 2 months ago
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
Objectives: We compared the effects of once-daily triple therapy on lung function and health-related quality of life with twice-daily ICS/LABA therapy in patients with COPD.
Added 3 months ago
Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while maintaining...
Added 2 months ago
Efficacy and Safety Study of QVA149 in COPD Patients
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while maintaining...
Added 2 months ago
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
Added 3 months ago
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
Added 3 months ago
A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The primary purpose of this study is to demonstrate improvements in lung function and health status for subjects treated with FF/UMEC/VI compared with budesonide/formoterol for 24 weeks.
Added 3 months ago
GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD.
Freshly updated for 2017, the latest edition of the Global Strategy document is the premiere evidence-based reference tool for the implementation of effective disease management plans, and represents the current best practices...
Added 11 months ago
Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases
The present guideline (S2k) on allergen-specific immunotherapy (AIT) was established by the German, Austrian and Swiss professional associations for allergy in consensus with the scientific specialist societies and professional associations...
Added 1 year ago
An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation
The purpose of this Statement is to update the 2006 document, including a new definition of pulmonary rehabilitation and highlighting key concepts and major advances in the field.
Added 4 years ago
Comments
You will need to login, to leave a comment.
epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.